ptc-1 Antibody

Basic Research Questions

• How to validate PTC-1 antibody specificity in immunohistochemistry (IHC)?

  • Method: Use positive and negative control tissues. For human samples, liver tissue shows consistent IHC positivity . Include antigen retrieval with TE buffer (pH 9.0) or citrate buffer (pH 6.0) . Validate with siRNA knockdown or CRISPR-Cas9 KO models to confirm loss of signal.

  • Data Validation:

    Tissue Type	Expected Result	Citation
    Human liver	Strong staining
    PTC tumors	Variable*
    *Dependent on PTCH1 expression levels in specific cancer subtypes.

• What are recommended dilutions for PTC-1 antibody in Western blot (WB)?

  • Protocol: Optimize using lysates from PTCH1-expressing cell lines (e.g., A431, HeLa) . Start with 1:500 dilution in 5% non-fat milk/TBST. Adjust based on signal-to-noise ratio.

  • Published Data:

    Application	Dilution Range	Observed MW
    WB	1:500–1:1000	161 kDa
    IHC	1:50–1:200	N/A

• How to address non-specific bands in WB with PTC-1 antibody?

  • Troubleshooting:

    • Pre-absorb antibody with PTCH1 knockout lysates.

    • Use high-stringency washes (0.1% Tween-20 in PBS).

    • Verify with secondary antibody-only controls.

Advanced Research Questions

• How does PTCH1 antibody performance vary across species in functional studies?

  • Experimental Design: Compare reactivity in human (Q13635), mouse (P97414), and rat models. The antibody shows confirmed reactivity in human and mouse tissues but requires validation for rat .

  • Key Finding:

    PTCH1 antibody detects endogenous protein in mouse brain and human liver tissues but fails to recognize C. elegans ptc-1 homologs .

• What experimental controls are critical for PTCH1 loss-of-function studies in cancer models?

  • Controls:

    • Positive: Hedgehog pathway agonists (e.g., SAG) to induce PTCH1 downregulation.

    • Negative: siRNA/CRISPR targeting PTCH1 vs. non-targeting controls.

    • Functional readout: Monitor downstream targets (e.g., GLI1) via qPCR .

• How to resolve discrepancies in PTCH1 subcellular localization across studies?

  • Analysis:

    • Membrane vs. cytoplasmic staining: Use fractionation WB (membrane/cytosolic splits) alongside IHC.

    • Context dependency: Tumor microenvironment (e.g., Hedgehog ligand availability) alters PTCH1 trafficking .

• What are limitations of using PTCH1 antibody in developmental biology models?

  • Challenge: PTCH1 isoforms (e.g., truncated variants in C. elegans) may evade detection .

  • Solution: Combine antibody staining with RNAscope™ for ptc-1 mRNA localization in C. elegans germline .

Data Contradiction Analysis

• Why do some studies report PTCH1 overexpression in tumors while others observe loss-of-function mutations?

  • Resolution:

    • Overexpression: Linked to compensatory feedback in Hedgehog-activated cancers (e.g., basal cell carcinoma) .

    • Mutations: Truncating mutations (e.g., basal cell nevus syndrome) abolish tumor suppressor activity despite high mRNA levels .

  • Experimental Design: Pair IHC with sequencing to distinguish protein expression vs. functional status.

Methodological Optimization

• How to adapt PTCH1 staining protocols for archival FFPE samples?

  • Optimization:

    • Prolong antigen retrieval to 45 minutes (pH 9.0).

    • Use signal amplification kits (e.g., Tyramide) for low-abundance targets .

• What in vitro assays best complement PTCH1 antibody-based studies?

  • Assays:

    • Co-IP: Validate PTCH1-SMO interactions in HEK293T overexpression systems.

    • Luciferase reporters: Quantify GLI-mediated transcription under PTCH1 modulation .